These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 10434891)

  • 61. MYC and MXI1 protein expression: potential prognostic significance in women with breast cancer in China.
    Xu LP; Sun Y; Li W; Mai L; Guo YJ; Fan QX
    Oncol Res Treat; 2014; 37(3):118-23. PubMed ID: 24685915
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Overall survival and PD-L1 expression in metastasized malignant melanoma.
    Gadiot J; Hooijkaas AI; Kaiser AD; van Tinteren H; van Boven H; Blank C
    Cancer; 2011 May; 117(10):2192-201. PubMed ID: 21523733
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Correlation of histopathologic characteristics to protein expression and function in malignant melanoma.
    Welinder C; Pawłowski K; Szasz AM; Yakovleva M; Sugihara Y; Malm J; Jönsson G; Ingvar C; Lundgren L; Baldetorp B; Olsson H; Rezeli M; Laurell T; Wieslander E; Marko-Varga G
    PLoS One; 2017; 12(4):e0176167. PubMed ID: 28445515
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The c-myc oncogene: use of a biological prognostic marker as a potential target for gene therapy in melanoma.
    Chana JS; Grover R; Tulley P; Lohrer H; Sanders R; Grobbelaar AO; Wilson GD
    Br J Plast Surg; 2002 Dec; 55(8):623-7. PubMed ID: 12550114
    [TBL] [Abstract][Full Text] [Related]  

  • 65. c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma.
    Chana JS; Wilson GD; Cree IA; Alexander RA; Myatt N; Neale M; Foss AJ; Hungerford JL
    Br J Ophthalmol; 1999 Jan; 83(1):110-4. PubMed ID: 10209447
    [TBL] [Abstract][Full Text] [Related]  

  • 66. c-myc is not useful as prognostic immunohistochemical marker in cutaneous melanoma.
    Böni R; Bantschapp O; Müller B; Burg G
    Dermatology; 1998; 196(3):288-91. PubMed ID: 9621133
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The current management and prognosis of acral lentiginous melanoma.
    Wells KE; Reintgen DS; Cruse CW
    Ann Plast Surg; 1992 Jan; 28(1):100-3. PubMed ID: 1642394
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cyclin D1 expression in acral melanoma: a case control study in Sarawak.
    Ibrahim ZA; Narihan MZ; Ojep DN; Soosay AE; Pan KL
    Malays J Pathol; 2012 Dec; 34(2):89-95. PubMed ID: 23424770
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The potential of oncogene products as tumour markers.
    Chan S; Sikora K
    Cancer Surv; 1987; 6(2):185-207. PubMed ID: 3322544
    [TBL] [Abstract][Full Text] [Related]  

  • 70. MicroRNAs in malignant melanoma.
    Völler D; Ott C; Bosserhoff A
    Clin Biochem; 2013 Jul; 46(10-11):909-17. PubMed ID: 23360785
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Insulin-Like Growth Factor II mRNA-Binding Protein 3 Expression Correlates with Poor Prognosis in Acral Lentiginous Melanoma.
    Sheen YS; Liao YH; Lin MH; Chiu HC; Jee SH; Liau JY; Chang YL; Chu CY
    PLoS One; 2016; 11(1):e0147431. PubMed ID: 26796627
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Different patterns of cell proliferation and death and oncogene expression in cutaneous malignant melanoma.
    Miracco C; Santopietro R; Biagioli M; Lazzi S; Nyongo A; Vatti R; Luzi P
    J Cutan Pathol; 1998 May; 25(5):244-51. PubMed ID: 9696289
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Expression of c-met tyrosine kinase receptor is biologically and prognostically relevant for primary cutaneous malignant melanomas.
    Cruz J; Reis-Filho JS; Silva P; Lopes JM
    Oncology; 2003; 65(1):72-82. PubMed ID: 12837985
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Prognostic tissue markers in melanoma.
    Moore DA; Pringle JH; Saldanha GS
    Histopathology; 2012 Apr; 60(5):679-89. PubMed ID: 21880059
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinicopathological significance of intratumoral and peritumoral lymphocytes and lymphocyte score based on the histologic subtypes of cutaneous melanoma.
    Park CK; Kim SK
    Oncotarget; 2017 Feb; 8(9):14759-14769. PubMed ID: 28107203
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Prognostic factors and survival in acral lentiginous melanoma.
    Asgari MM; Shen L; Sokil MM; Yeh I; Jorgenson E
    Br J Dermatol; 2017 Aug; 177(2):428-435. PubMed ID: 28432682
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Protein kinase C alpha associates with phospholipase D1 and enhances basal phospholipase D activity in a protein phosphorylation-independent manner in human melanoma cells.
    Oka M; Kageshita T; Ono T; Goto A; Kuroki T; Ichihashi M
    J Invest Dermatol; 2003 Jul; 121(1):69-76. PubMed ID: 12839565
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Acral lentiginous melanoma in situ.
    David SS; Ramakrishna B
    Eur J Surg; 1992 Apr; 158(4):247-8. PubMed ID: 1352141
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival Analysis.
    Kolla AM; Vitiello GA; Friedman EB; Sun J; Potdar A; Daou H; Farrow NE; Farley CR; Vetto JT; Han D; Tariq M; Beasley GM; Contreras CM; Lowe M; Zager JS; Osman I; Berman RS; Liebman TN; Stein JA; Lee AY
    Cancer Control; 2021; 28():10732748211053567. PubMed ID: 34752172
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Genetic markers of melanoma].
    Tronov VA; Artamonov DN; Gorbacheva LB
    Genetika; 2010 Feb; 46(2):168-79. PubMed ID: 20297650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.